The FDA has approved Labcorp’s PGDx elio tissue complete CDx, a kit-based NGS companion diagnostic, to identify BRAF variants and guide targeted therapy selection for patients with advanced melanoma.
A new study introduced an AI-powered diagnostic model with 94.49% accuracy to improve skin cancer detection and patient outcomes.
The molecular Skin Fluorescence Imaging System noninvasively identifies and assesses activity associated with melanoma development.
When T cells are activated they release the CXCL13 protein, which helps attract more B cells and T cells to the tumor site.
Read More
A new patient-centered approach more accurately identifies melanoma patients eligible for sentinel lymph node biopsy (SLNB).
Read More
DermaSensor presented a pooled analysis from clinical studies evaluating the performance of the company’s device in detecting skin cancer.
Read More
The U.S. General Services Administration has recommended DermTech’s foundational melanoma assay for coverage by the VHA.
Read More
Researchers found potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to cause progression of melanoma cells.
Read More
Roche has announced the launch of the PRAME Antibody to identify PRAME protein expression with suspected melanoma.
Read More
Proscia released study results on new AI that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.
Read More
Unilabs and Proscia have announced that the diagnostic group has chosen Proscia’s DermAI skin pathology solution.
Read More
InterVenn’s new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
Read More
Researchers have discovered blood biomarkers that can help identify if someone suffering from Melanoma can benefit from immune checkpoint inhibitors.
Read More
FoundationOne CDx is used as a companion diagnostic for two groups of FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies.
Read More
Researchers used deep learning framework to transform microscopy images of intact skin into histochemically stained sections imaged on microscope slides.
Read More
Proscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.
Read More
Castle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.
Read More
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read More